PHILIPPINES PART OF MERCK'S GLOBAL EXPANSION STRATEGY
SGP | Quote | Chart | News | PowerRating -- Merck & Co., Inc. has outlined
its global strategy following the completion of Merck's merger
with Schering-Plough Corporation.
The new Merck, operating as MSD outside the United States
and Canada, is a global health care leader aimed at providing
innovative, distinctive products and services that save and
improve lives, while satisfying customer needs and creating
long-term shareholder value.
The Philippines is an integral part of the company's
expanded global presence.
MSD is fully committed to bringing innovative medicines and
vaccines to Filipinos as well as undertaking educational
efforts that benefit patients and doctors and social programs
that build the capacity of health professionals and
non-government organizations (NGOs) to improve healthcare in
the country.
Although MSD and Schering-Plough will remain separate legal
entities in the Philippines for a period of time, their
operations will eventually be integrated under the MSD name.
Chris Tan, managing director of MSD Philippines, commented,
This is an exciting time for our company as we advance our
position as a strong, global health care leader that will make
a substantial difference to patients around the world."
He added, "Thanks to the talent and dedication of our
scientists and employees, the company will offer an outstanding
clinical development pipeline that will greatly increase our
ability to deliver important new medicines to patients. "We
look forward to continuing to meet and exceed the needs of our
customers and providing them with the high-quality products and
service they have come to expect.
From the outset, Merck is a global health care leader with a
diversified portfolio of prescription medicines, vaccines and
animal and consumer health products.
This portfolio is complemented by a robust pipeline with
more than 15 promising late-stage candidates spanning critical
therapeutic categories. Merck now has approximately 106,000
employees and operations in more than 140 countries around the
world, including emerging markets.
The company expects to generate more than 50 per cent of its
revenue outside the United States.
(PNA)
For full details on Schering-Plough Corp (SGP) SGP. Schering-Plough Corp (SGP) has Short Term PowerRatings at TradingMarkets. Details on Schering-Plough Corp (SGP) Short Term PowerRatings is available at This Link.
For full details on Merck & Co (MRK) MRK. Merck & Co (MRK) has Short Term PowerRatings at TradingMarkets. Details on Merck & Co (MRK) Short Term PowerRatings is available at This Link.
- AnaptysBio announces collaboration with Merck - 02/09/10
- Critical Alerts for Merck, Lowe's, MEMC Electronic Materials, Lennar, and Kinross Gold Released by Seven Summits Research - 02/09/10
- Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results - 02/09/10
- Emerging Combination Agent from Merck Will Garner Peak Year Sales of More Than $250 Million for the Treatment of Asthma - 02/08/10
- AnaptysBio Announces Strategic Collaboration with Merck & Co., Inc. - 02/08/10
- More News >>
